Structure Therapeutics appoints Blai Coll as CMO, Ashley Hall as CDO; Mark Bach departs in planned succession

Structure Therapeutics Inc.

Mark Bach to depart as CMO effective Sept 18; will serve as advisor through Dec 31.
Blai Coll, previously VP of Clinical Development, promoted to CMO effective Sept 18.
Ashley Hall appointed as newly created Chief Development Officer role.
GSBR-1290 Phase 2b for obesity planned for Q4 2024.
Dr. Coll led GSBR-1290 program; Ms. Hall brings regulatory experience from Repatha.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Bach

Chief Medical Officer

GPCR · Structure Therapeutics Inc.

Effective: 2024-09-18
Filed: September 17, 2024, 7:59 PM ET

On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the “Bach Separation and Consulting Agreement”) with Structure Therapeutics Inc. (the “Company”) in connection with his departure as Chief Medical Officer (“CMO”) as part of a planned succession, effective as of September 18, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Bach departed as Chief Medical Officer at Structure Therapeutics Inc..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the “Bach Separation and Consulting Agreement”) with Structure Therapeutics Inc. (the “Company”) in connection with his departure as Chief Medical Officer (“CMO”) as part of a planned succession, effective as of September 18, 2024 (the “Effective Date”).

View on SEC.gov

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-100668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.